Category | 2022 1H |
2022 2H |
2023 1H |
2023 2H |
2024 1H |
2024 2H |
Target indication | |
---|---|---|---|---|---|---|---|---|
BRIXELLE-INFLA | ||||||||
Acute inflammatory disease |
IV |
CMC, PK & Tox
|
IND Sub.
|
Phase I
|
Phase II
|
Ischemic Reperfusion Injury(Organ Transplant, AKI, AMI, CABG, Stroke) | ||
Chronic inflammatory disease |
SC/PO |
Efficacy & MoA
|
Formulation dev.
|
PK & Tox
|
TBD (MS, IBD, Asthma, etc.) |
|||
Skin disease |
Topical |
Efficacy & MoA
|
Formulation dev.
|
PK & Tox
|
Atopic dermatitis, Psoriasis, etc. | |||
BRIXELLE-ONCO | ||||||||
Drug delivery system | IV |
DDS characterization
|
Efficacy & MoA
|
Formulation dev.
|
PK & Tox
|
Cancer | ||
Discovery projects | ||||||||
Discovery projects |
Project A |
Discovery
|
Efficacy & MoA
|
TBD | ||||
Project B |
Discovery
|
Efficacy
|
TBD | |||||
Project C |
Discovery
|
TBD | ||||||
If you are interested in our pipeline, please contact us. |
2020-05-25